bluuebunny/crossref_metadata_2025_split huggingface dataset:
Phase I–II trial of VP‐16 in the treatment of acute nonlymphocytic leukemia and blast crisis of chronic granulocytic leukemia
Authors: Mailliard James A. , Letendre Louis , Dalton Robert J. , Levitt Ralph , Gerstner James B. , Therneau Terry M. , Pierre Robert V. 
Published: February 2007

AbstractVP‐16 was used to treat newly diagnosed elderly (⩾65 yr) patients with acute nonlymphocytic leukemia (ANLL) and patients with blast crisis of chronic granulocytic leukemia (BI‐CGL). Our pilot study indicated that VP‐16 160 mg/m2 intravenously daily for 5 days was well tolerated and suggested a direct dose‐response correlation. Thirty additional ANLL patients and 11 CGL patients were studied. Among 26 evaluable ANLL patients, we observed ten responses (38%) (seven complete remission and three partial remission), but none of 11 patients with CGL in blast crisis had meaningful responses. In patients who responded to treatment, myelosuppression was always reversed by day 25. Stomatitis was the major nonhematologic toxicity and appeared more severe with advancing age. We conclude that VP‐16 is active against ANLL and is well tolerated at doses higher than have been previously described. It remains to be shown that the present schedule is superior to the intermittent high‐dose or continuous low‐dose infusion schedules, which have been recently described.
Effect of transfusions on serologic testing for antibody to varicella
Authors: Taylor‐Wiedeman Jean , Brunell Philip A. , Geiser Clementina , Shehab Ziad M. , Frierson Lisa S. 
Published: February 2007

AbstractSerologic testing of patients with acute lymphocytic leukemia for susceptibility to varicella was confounded by prior administration of blood products. Packed red cell transfusions produced fewer problems than plasmarich transfusions. Seronegative individuals may be transiently seropositive for several weeks. Specimens submitted for serologic testing should be accompanied by information on recent receipt of blood products.
Fat embolization and pulmonary infiltrates after bone marrow transplantation
Authors: Lipton J. H. , Russell J. A. , Burgess K. R. , Hwang W. S. 
Published: February 2007

AbstractPulmonary interstitial infiltrates developed in a 22‐year‐old female after bone marrow transplantation (BMT) for acute lymphoblastic leukemia (ALL) in second remission. She was receiving prednisone for graft versus host disease (GvH). There was some evidence of cardiac failure, but the primary diagnosis was that of cytomegalovirus (CMV) pneumonia, which resolved. Recurrent infiltrates were associated with the appearance of fat emboli in the pulmonary capillaries. There was little histological evidence of CMV pneumonitis, although other tests confirmed persistent infection. The patient recovered after further treatment directed at CMV infection and cardiac failure with a modest reduction in steroid dose. Most previous descriptions of pulmonary fat embolization (PFE) in immunocompromised patients have been derived from autopsy studies, and the majority of patients have received steroid therapy. The present case illustrates that PFE may complicate or contribute to the picture of interstitial pneumonitis (IPN) in the BMT recipient and that this syndrome may be reversible.
Treatment of neuroblastoma with 131I‐metaiodobenzylguanidine: The experience of an Italian study group
Authors: Bestagno M. , Guerra P. , Puricelli G. P. , Colombo L. , Calculli G. 
Published: February 2007

AbstractEight patients affected by neuroblastoma were treated with 18 courses of 131I‐meta‐iodobenzylguanidine (MIBG). They all had been judged as “nonresponders” to conventional treatments. Six had stage IV disease: of these, five, with massive marrow involvement, had poor results, mainly because of marrow depression; one, whose marrow had been previously purged by chemotherapy, showed a decrease in blood cell counts but not to critical levels, thus allowing repeated treatments and some improvement. Two other cases had stage III disease, without marrow involvement. Both could receive repeated treatments without adverse effects on marrow and circulating blood cells; both could have surgical procedures when a significant neoplastic mass reduction had been induced by MIBG treatments.Almost all patients experienced reduction or disappearing of pain. Treatments were well tolerated.
Retroperitoneal sarcomas: The role of diagnostic imaging and multimodal management
Authors: Silberman Allan W. , Steckel Richard J. , Kagan A. Robert 
Published: February 2007

AbstractRetroperitoneal sarcomas are a varied group of malignancies which have a high rate of recurrence following surgery alone. The majority of the initial recurrences are local in nature, and new therapeutic approaches are clearly needed. Diagnostic imaging and “interventional radiology” have important roles to play in the management of these malignancies, as well as in investigational approaches to therapy. Two cases are presented which illustrate some recent advances in diagnosis and staging of this group of tumors which can be attributed to new cross‐sectional imaging techniques, when used in concert with “conventional” imaging methods. The latter include arteriography to guide the placement of intra‐arterial catheters for local infusion chemotherapy. CT‐guided needle biopsies can be performed to secure a preoperative diagnosis and also to obtain viable tissue for in vitro chemosensitivity assays. A judicious combination of local and systemic chemo therapy, radiation, and surgery may hold promise for better control of this malignancy, similar to the therapeutic advances which have already been obtained with limb sarcomas.
Catching up with history: Treatment of Wilms' tumor in a developing country
Authors: De Camargo Beatriz , De Andrea Maria Lydia M. , Franco Eduardo L. F. 
Published: February 2007

AbstractI Despite the tremendous progress that pediatric oncology has achieved in the treatment of Wilms' tumor over the last several decades, survival rates in our institution before 1970 did not exceed 8%. In order to correct the problem standardized therapy was instituted in 1970 through a multimodal oncological team. Results using the new approach were reviewed in 1979 (50 patients) and showed an overall 34% 2‐year survival rate. Although encouraging, these results were still far below the ones reported in the literature. This prompted us to use a vigorous professional and lay educational program in the city. Treatment methods were replaced by those advocated by the Second National Wilms' Tumor Study. A second evaluation period initiated in 1979 and extended through 1984 (35 patients) yielded an overall 83% survival rate. A retrospective study of the two periods by univariate and multivariate survival analysis revealed that, although much of the improvement in survival could be attributed to a shift in stage distribution towards earlier disease, the admission period itself had an important additional explanatory effect with respect to survival. This was probably due to the improvement in treatment protocols used in the latter period. Age was a prognostic variable only for patients admitted during the 1979‐1984 period.
Precocious puberty associated with malignant thoracic teratoma and malignant histiocytosis in a child with Klinefelter's syndrome
Authors: Beasley S. W. , Tiedemann K. , Howat A. , Werther G. , Auldist A. W. , Tuohy P. 
Published: February 2007

AbstractA 10‐year‐old boy with precocious puberty of 2 1/2 years' duration presented with a malignant thoracic teratoma with elevated levels of beta human chorionic gonadotrophin (β‐HCG) and alpha fetoprotein (αFP). The mediastinal tumor was completely excised and adjuvant chemotherapy commenced. Within 3 weeks of commencing chemotherapy he developed hematologic abnormalities that, with the subsequent clinical illness, led to a diagnosis of malignant histiocytosis. Death occurred a few days after start of therapy for malignant histiocytosis. Cytogenic studies showed the somatic karyotype to be that of Klinefelter's sydrome, while the malignant cells in marrow and lymph node carried an additional marker chromosome. This case, with others reported, suggest that the XXY karyotype may influence the development of mediastinal germ cell tumors, which in themselves appear to be associated with the early onset of a malignancy of the hemopoietic system.
Salvage chemotherapy for lymphoma with VP‐16, ifosfamide, and cisplatin
Authors: Nichols Craig R. , Loehrer Patrick J. , Greist Anne , Kubilis Paul S. , Hoffman Ronald 
Published: February 2007

AbstractBetween 1983 and 1985, we conducted a phase II clinical trial using VP‐16, ifosfamide, and cisplatin (VIP) in patients with refractory lymphoma. Twenty‐eight patients with bidimensional measurable disease were treated with VP‐16 (75 mg/m2), ifosfamide (1.2 g/m2), and cisplatin (20 mg/m2) as daily intravenous infusions for 5 consecutive days. N‐Acetyl‐cystein, 2 g orally every 6 h, was given as a uroepithelial protective agent. All patients had received extensive combination chemotherapy prior to beginning VIP (median number of regimens = 2). Of the 25 patients evaluable for response, 2 patients achieved complete remission and 7 achieved partial remission for an overall objective response rate of 36%. The length of responses ranged from 2 months to 13 months. The predominant toxicity of VIP was myelosuppression. Of 23 patients receiving more than one course of VIP, 17 (73%) had dose reductions or delays related to poor hematologic tolerance of therapy. Uroepithelial and renal toxicity were mild. VIP demonstrates therapeutic activity in refractory lymphoma and appears comparable to other ifosfamide/VP‐16 based salvage regimens.
Treatment of myelodysplastic syndromes with low‐dose oral 6‐thioguanine
Authors: Spitzer Thomas R. , Lazarus Hillard M. , Crum Edward D. , Weisman Russell 
Published: February 2007

AbstractSeveral cytotoxic agents when used in vitro in very low concentrations have been shown to induce differentiation of leukemic cells. We treated 18 patients with myelodysplastic syndromes with low‐dose oral 6‐thioguanine (6‐TG; 20 to 60 mg daily). Four patients demonstrated significant improvement in peripheral blood counts. An additional three patients had significant reductions in the percentage of leukemic myeloblasts in the marrow without a corresponding improvement in peripheral counts. With the exception of a fall in the peripheral neutrophil count in four patients requiring dose reductions, no toxicity was observed. Low‐dose oral 6‐TG gives a response rate in myelodysplastic syndromes similar to that of parenteral agents such as cytosine arabinoside. Given the ease of administration and lack of toxicity, oral 6‐TG may be a useful treatment modality for these syndromes either alone or in combination with other differentiation‐enhancing agents.
Phase II trial of 4′‐deoxydoxorubicin (DxDx) in non‐small cell lung cancer: A cancer and leukemia group B trial
Authors: Ringenberg Q. Scott , Perry Michael C. , Propert Kathleen J. , Modeas Caron , Hirsh Vera , Weiss Raymond B. , Richards Frederick , Graziano Stephen , Green Mark 
Published: February 2007

AbstractEighty‐seven patients with histologically or cytologically proven non‐small‐cell carcinoma of the lung were treated with 4′‐deoxydoxo‐rubicin (DxDx) 30 mg/m2 every 3 weeks. Three responses (4%), all partial, were observed. All responses occurred in patients with large‐cell anaplastic lung cancer and none in squamous or adenocarcinoma histologies (P < 0.01). The durations of partial response for these three responders were 70, 198+ and 209+ days. The side effects noted were predominantly neutropenia, anemia, and weight loss. In three patients, declines in cardiac ejection fraction of 7%, 12%, and 23% occurred after cumulative drug doses of 150 mg/m2, 150 mg/m2, and 233 mg/m2, respectively. 4′‐Deoxydoxorubicin had little activity in non‐small‐cell lung cancer at the dose used in this study.
Congenital anomalies associated with rhabdomyosarcoma: An autopsy study of 115 cases. A report from the intergroup rhabdomyosarcoma study committee (representing the children's cancer study group, the pediatric oncology group, the United Kingdom children's cancer study group, and the pediatric intergroup statistical center)
Authors: Ruymann Frederick B. , Maddux Helen R. , Ragab Abdel , Soule Edward H. , Palmer Nigel , Beltangady Mohan , Gehan Edmund A. , Newton William A. 
Published: February 2007

AbstractCongenital anomalies were identified in 37 of 115 (32%) children and adolescents autop‐sied with rhabdomyosarcoma. An analysis of sex, age, site, and histology of cases with or without congenital anomalies showed no significant differences. Of the 45 identified anomalies, 14 were considered major and 31 minor. The distribution of the anomalies by system included central nervous (9), genitourinary (10), gastrointestinal (13), and cardiovascular systems (4). Ten patients had complex or miscellaneous anomalies. There was one child with each of the following: Rubinstein‐Taybi syndrome, neurofibromatosis, single horseshoe kidney, hemihypertrophy, and Arnold‐Chiari malformation. Aniridia was not noted in any case of rhabdomyosarcoma. Individuals with rhabdomyosarcoma have an increased incidence of genitourinary anomalies similar to that in Wilms' tumor. Recent molecular genetic investigations have suggeted that rhabdomyosarcoma, Wilms' tumor, and he‐patoblastoma share a common pathogenetic mechanism involving chromosome 11. The uniquely increased association of central nervous system anomalies with rhabdomyosarcoma and absence of aniridia would support a different gene locus operative on chromosome 11 for individuals with rhabdomyosarcoma compared to Wilms' tumor. Extensive epidemiologic studies now in progress in patients with rhabdomyosarcoma should provide the incidence of congenital anomalies and potential linkage with prenatal events.
Possible association of human growth hormone treatment with an occurrence of acute myeloblastic leukemia with an inversion of chromosome 3 in a child of pituitary dwarfism
Authors: Endo Machiko , Kaneko Yasuhiko , Shikano Takaaki , Minami Hideki , Chino Jun‐Ichi 
Published: February 2007

AbstractAn 11–yr‐old girl, who had been treated with human growth hormone (h‐GH) for 31 months, developed acute myeloblastic leukemia with an inv(3)(q21q26). Since CH has been suggested to influence the genesis of leukemia, and the inversion 3 has been reported only in adult leukemia patients, the GH treatment may have caused the development of leukemia or accelerated the proliferation of the leukemia cells.
Childhood hepatic mesenchymoma: Successful treatment with surgery and multiple‐agent chemotherapy
Authors: Ware Russell , Friedman Henry S. , Filston Howard C. , Chaffee Sara , Kurtzberg Joanne , Kinney Thomas R. , Falletta John M. 
Published: February 2007

AbstractMalignant undifferentiated sarcoma (mesenchymoma) of the liver is a rare tumor of childhood, with fewer than 100 cases reported in the literature. The overall prognosis for patients with this malignancy is poor. In this report, two children with hepatic mesenchymoma underwent surgical excision followed by 2 years of adjuvant chemotherapy. Rotating cycles of cisplatinum, vincristine/doxorubicin, vincristine/cyclophosphamide, and vincristine/actinomycin D were given with minimal toxicity. Both patients are alive, with no evidence of disease at least 5 years from diagnosis. Previous reports of treatment are reviewed.
Prognostic factors in 281 children with nonmetastatic rhabdomyosarcoma (RMS) at diagnosis
Authors: Rodary C. , Rey A. , Olive D. , Flamant F. , Quintana E. , Brunat‐Mentigny M. , Otten J. , Voute P. A. 
Published: February 2007

AbstractPretreatment characteristics of 281 children with nonmetastatic rhabdomyosarcoma, included in the registry of the International Society of Pediatric Oncology (SIOP) between January 1975 and December 1983, were examined to study the children's prognosis. The multivariate statistical method (Cox regression model) was used for each of two end‐points: survival time and disease‐free time.The three most important predictors for survival time were primary site (p < .001), clinical stage (p = .009), and sex (p = .020). The best results involved paratesticular and orbital primary sites, regardless of the clinical stage; males fared slightly better than females. These same three factors were also significant predictors for disease‐free time.
Malignant disease in the mothers of children with Ewing's tumour
Authors: Hartley A. L. , Birch J. M. , Marsden H. B. , Harris M. , Blair V. 
Published: February 2007

AbstractPrevious research has shown that mothers of children with soft tissue sarcoma, osteosarcoma, and chondrosarcoma are at excess risk of developing breast cancer. The occurrence of malignant disease in the mothers of a population‐based series of children with Ewing's sarcoma was investigated in order to determine whether these mothers were at excess risk of cancer and of breast cancer in particular. Sixty‐one mothers were traced; there were two cases of breast cancer and two other registrable neoplasms. Risk of malignancy in the mothers was not in excess of expectation.
Effectiveness of attenuated chemotherapy in myelodysplastic syndromes: A preliminary report
Authors: Owens Michael R. , Bennett John M. 
Published: February 2007

AbstractA small group of elderly male patients received attenuated doses of daunomycin, cytosine arabinoside (Ara‐C), and 6‐thioguanine for treatment of myelodysplastic syndrome (MDS). Three patients had refractory anemia with excess blasts (RAEB), and two had chronic myelomonocytic leukemia (CMMoL). All five patients had developed severe transfusion requirements for platelets and red blood cells before therapy was begun. One patient developed necrosis of the cecum and expired 19 days after therapy, but the other four all showed substantial benefit from treatment. Three of those patients received multiple courses of chemotherapy which led to improvement in peripheral blood counts in each case. Duration of responses as noted by improvement in peripheral blood counts compared to pretreatment levels ranged from 1.5 to 9 months. Despite considerable improvement in peripheral blood parameters, some of the abnormal morphologic features of MDS persisted after each course of chemotherapy. These results obtained with attenuated chemotherapy schedules in a small group of patients are sufficiently encouraging to warrant an expanded phase II trial, which is under way at the University of Rochester Cancer Center.
Preliminary experience with chemotherapy in advanced salivary gland neoplasms
Authors: Belani Chandra P. , Eisenberger Mario A. , Gray William C. 
Published: February 2007

AbstractEight patients with advanced incurable salivary gland carcinoma were treated with the combination of cyclophosphamide, doxorubicin, and cisplatin (CAP). There were three clinical complete responses and two excellent partial responses. One of the three nonresponders had symptomatic improvement without any response in the measurable disease sites. Side effects were acceptable. All patients had moderate nausea and some degree of vomiting, which were adequately controlled by antiemetics. These results are preliminary but when considered with other reported trials using the same combination suggest an active treatment program for advanced neoplasms of the salivary glands.
Reproductive problems and birth defects in survivors of Wilms' tumor and their relatives
Authors: Byrne Julianne , Mulvihill John J. , Connelly Roger R. , Austin Donald A. , Holmes Grace E. , Holmes Frederick F. , Latourette Howard B. , Meigs J. Wister , Strong Louise C. , Myers Max H. 
Published: February 2007

AbstractIn a retrospective cohort study of 47 Wilms' tumor survivors and their 77 sibling controls, female survivors had a fourfold excess risk (risk ratio, 4.1; 95% confidence interval, 1.7‐10.1) for any adverse livebirth outcome, including birth defects, compared with their sibling controls. Wives of male survivors had no apparent excess risk for problem pregnancies. The families had a number of severe reproductive problems and major birth defects, such as primary amenorrhea in two survivors, bicornuate uterus in two survivors and one control, and mental retardation in one male survivor and a male control. The son of a female survivor died after bilateral Wilms' tumors. Birth defects in the offspring of female survivors are compatible either with intrauterine constraint, possibly due to radiation‐induced fibrosis or with the complex of malformations associated with Wilms' tumor. Female survivors of Wilms' tumor appear to be at increased risk for a variety of reproductive problems, from sterility to fetal loss, early delivery, and birth defects in offspring. Furthermore, relatives of survivors of Wilms' tumor may be at risk of having associated birth defects, with clinically significant consequences.
Male reproductive function in long‐term survivors of childhood cancer
Authors: Jaffe Norman , Sullivan Margaret P. , Ried Hubert , Boren Hallie , Marshall Robert , Meistrich Marvin , Maor Moshe , Cunha Miguel Da 
Published: February 2007

AbstractWe evaluated reproductive function in 27 male long‐term survivors of childhood cancer treated during the prepubertal and pubertal period. Sperm samples were obtained from 23 patients; four who refused to provide specimens indicated that they had fathered normal healthy children. Thirteen patients were 12 years old or younger at the time of diagnosis and initiation of therapy. Chemotherapy was calculated according to the cumulative amount of drug administered and correlated with the surface area. Sterility was associated with large doses of single alkylating agents or reduced doses administered with other agents in combination regimens. It was noted in boys treated in both the prepubertal and pubertal period. Sterility was also observed in patients who received testicular radiation alone or in combination with chemotherapy. However, it was not an inevitable consequence in all patients, despite treatment with similar or identical regimens. Fertility potential could not be predicted by clinical examination (testicular size) or gonadotrophin and testosterone values. The results were compared to published reports of treatmentinduced sterility in adult males. Additional investigations are required to establish more accurate correlations of dosage with reproductive potential.
Pneumonia carcinomatosa from small cell undifferentiated carcinoma of the lung presenting as “reverse radiation pneumonitis”
Authors: Adelstein David J. , Padhya Tushar , Tomashefski Joseph F. , Park Chanho 
Published: February 2007

AbstractWe describe a patient with recurrent small cell undifferentiated lung carcinoma after chemotherapy and mediastinal radiation therapy who presented with peripheral pulmonary infiltrates on chest radiograph. At autopsy the patient was found to have carcinomatous pneumonia confined to the radiographically abnormal lung. The descriptive term “reverse radiation pneumonitis” is applied in view of the striking non segmental distribution of these pulmonary infiltrates, which occurred only outside the irradiated field. In this patient, radiation therapy successfully controlled disease in the treated lung parenchyma, thus accounting for this unusual radiologic and histologic picture. Pneumonia carcinomatosa, occurring after lung irradiation, can therefore be added to the differential diagnosis of radio‐graphic peripheral pulmonary infiltrates.